Washington, D.C., 2 April 2017- American Association for Cancer Research(AACR) Bestows 2017 Team Science Award to a Renowned Team of Investigators who Pioneered the Science of Liquid Biopsy:Luis A. Diaz, Nishant Agrawal, Chetan Bettegowda, Frank Diehl, Peter Gibbs, Stanley R. Hamilton, Ralph H. Hruban, Hartmut Juhl, Isaac Kinde, Kenneth Kinzler, Martin Nowak, Nickolas Papadopoulos, David Sidransky, Jeanne Tie, Victor E. Velculescu, Bert Vogelstein
PapGene, Inc. announced today that its Chief Scientific Officer, Isaac A. Kinde, M.D., Ph.D., a nationally recognized expert in molecular cancer diagnostics, is a recipient of the AACR 2017 Team Science Award for advancing the science of Liquid Biopsies. As a joint M.D. and Ph.D. student at the Johns Hopkins University, Dr. Kinde contributed to the creation of multiple patented technologies which advanced the detection sensitivity of liquid biopsies. Upon graduating from Johns Hopkins, Dr. Kinde helped found PapGene where the technologies he co-invented are being applied to identify patients with early-stage cancers. The AACR award announcement highlighted the team’s achievements stating, “The work of this outstanding interdisciplinary team on the application of cancer mutations as specific diagnostic biomarker, represents a major advance in the translation of basic research into clinical cancer applications. Each team member has made important contributions in the conceptualization, development, and application of somatic mutations as dynamic biomarkers in liquid biopsies of solid tumor malignancies”. Dr. Kinde said of the award, “This award recognizes the contributions of many outstanding scientists who have collaborated to advance the state of the art of detecting early stage cancers when most cancers are curable by conventional surgical procedures”. Kinde further elaborated by saying “PapGene is in the process of demonstrating the clinical utility of many of these advancements to make them available to the clinical community”.
About the AACR Team Award
The AACR Team Award has been established by the American Association for Cancer Research and Eli Lilly and Company to acknowledge and catalyze the growing importance of interdisciplinary teams to the understanding of cancer and/or the translation of research discoveries into clinical cancer applications. Proactive interaction between academic and industry researchers is particularly crucial to continue progress and accelerate drug development. In addition, through the presentation of this award, the AACR and Eli Lilly seek to effect change within the traditional cancer research culture by recognizing those institutions that value and foster interdisciplinary team science.
About PapGene, Inc.
PapGene is a molecular diagnostic company dedicated to advancing the early detection of curable cancers. The company is developing innovative tests that uncover early-stage cancers from the analysis of easily accessible body fluids. The company’s assays detect cancers while they are still surgically resectable by identifying the presence of genetic defects (acquired mutations) that drive cancer growth.
For more information, please visit http://www.papgeneinc.com
Chief Executive Officer
PapGene, Inc. firstname.lastname@example.org
Share this Post